BindingDB logo
myBDB logout

100 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27774126 95 ExploringEBI University of California-San Francisco
26753814 7 Cyclic RGD peptidomimetics containing 4- and 5-amino-cyclopropane pipecolic acid (CPA) templates as dualaV▀3 anda5▀1 integrin ligands.EBI University of Florence
24949551 22 Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptides.EBI Philipps-Universit£t Marburg
24973662 8 Targeting integrinsav▀3 anda5▀1 with new▀-lactam derivatives.EBI University of Bologna
24654918 19 Pharmacophoric modifications lead to superpotentav▀3 integrin ligands with suppresseda5▀1 activity.EBI Technische Universit£t M£nchen
9873531 3 Novel inhibitors of alpha 4 beta 1 integrin receptor interactions through library synthesis and screening.EBI University of California
24412498 15 Synthesis and assay of retro-a4▀1 integrin-targeting motifs.EBI University of Bologna
24095096 3 Synthesis and in vitro evaluation of a novel radioligand forav▀3 integrin receptor imaging: [18F]FPPA-c(RGDfK).EBI University Hospital of Geneva
23811088 26 Modulation ofav▀3- anda5▀1-integrin-mediated adhesion by dehydro-▀-amino acids containing peptidomimetics.EBI University of Bologna
23777782 107 Orally available and efficaciousa4▀1/a4▀7 integrin inhibitors.EBI Elan Pharmaceuticals
23312947 22 Synthesis and evaluation of 4,5-dihydro-5-methylisoxazolin-5-carboxamide derivatives as VLA-4 antagonists.EBI Ranbaxy Research Laboratories
23562062 4 Arylsulfonamide pyrimidines as VLA-4 antagonists.EBI Elan Pharmaceuticals, Inc.
23362923 59 Biselectivity of isoDGR peptides for fibronectin binding integrin subtypesa5ß1 andavß6: conformational control through flanking amino acids.EBI Technische Universit£t M£nchen
23312474 36 Identification of N-acyl 4-(5-pyrimidine-2,4-dionyl)phenylalanine derivatives and their orally active prodrug esters as dual-acting alpha4-beta1 and alpha4-beta7 receptor antagonists.EBI Hoffmann-La Roche Inc.
23312471 31 Identification of N-acyl 4-(3-pyridonyl)phenylalanine derivatives and their orally active prodrug esters as dual actinga4ß1 anda4ß7 receptor antagonists.EBI Hoffmann-La Roche Inc.
23218775 38 A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid.EBI Daiichi Sankyo Co., Ltd
22261021 33 Identification of trans-4-[1-[[7-fluoro-2-(1-methyl-3-indolyl)-6-benzoxazolyl]acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid as a potent, orally active VLA-4 antagonist.EBI Daiichi Sankyo Co., Ltd
22101134 9 LDV peptidomimetics equipped with biotinylated spacer-arms: synthesis and biological evaluation on CCRF-CEM cell line.EBI Universit£ catholique de Louvain (UCL)
21889349 20 Modeling the molecular basis fora4ß1 integrin antagonism.EBI Ian Wark Laboratories
16767086 2 Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging.EBI University of California
19959360 50 SAR of N-phenyl piperidine based oral integrin alpha5beta1 antagonists.EBI Jerini AG
19910191 46 Discovery of orally available integrin alpha5beta1 antagonists.EBI Jerini AG
19713111 31 Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3',5'-dichloro-isonicotinoyl) amino]-(l)-phenylalanine (MK-0617), a highly potent and orally active VLA-4 antagonist.EBI Merck Research Laboratories
19891440 57 Discovery of trans-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid: an orally active, selective very late antigen-4 antagonist.EBI Daiichi Sankyo Co., Ltd.
16039122 9 Influence of acid surrogates toward potency of VLA-4 antagonist.EBI Merck Research Laboratories
15582407 20 Identified a morpholinyl-4-piperidinylacetic acid derivative as a potent oral active VLA-4 antagonist.EBI Daiichi Pharmaceutical Co. Ltd
15582442 36 2,3-Diphenylpropionic acids as potent VLA-4 antagonists.EBI Kaken Pharmaceutical Co. Ltd
12086484 13 Identification of potent and novel alpha4beta1 antagonists using in silico screening.EBI Biogen Inc.
9341911 133 Potent alpha 4 beta 1 peptide antagonists as potential anti-inflammatory agents.EBI Genentech Inc.
12617895 30 Dehydrophenylalanine derivatives as VLA-4 integrin antagonists.EBI Celltech R&D Ltd
14552799 14 Sulphonamide-based small molecule VLA-4 antagonists.EBI Molecumetics
12749892 42 N-isonicotinoyl-(L)-4-aminophenylalanine derivatives as tight binding VLA-4 antagonists.EBI Merck Research Laboratories
11858990 20 N-aryl 2,6-dimethoxybiphenylalanine analogues as VLA-4 antagonists.EBI Merck Research Laboratories
11844701 5 Identification of unique VLA-4 antagonists from a combinatorial library.EBI Merck Research Laboratories
11755339 33 N-acyl-L-phenylalanine derivatives as potent VLA-4 antagonists that mimic a cyclic peptide conformation.EBI Hoffmann-La Roche Inc.
12161162 69 N-Aroyl-L-phenylalanine derivatives as VCAM/VLA-4 antagonists.EBI Hoffmann-La Roche Inc.
12039570 51 N-(pyrimidin-4-yl) and N-(pyridin-2-yl) phenylalanine derivatives as VLA-4 integrin antagonists.EBI Celltech R&D Ltd
12039569 36 Discovery and evaluation of N-(triazin-1,3,5-yl) phenylalanine derivatives as VLA-4 integrin antagonists.EBI Celltech R&D Ltd
12031328 21 N-Tetrahydrofuroyl-(L)-phenylalanine derivatives as potent VLA-4 antagonists.EBI Merck Research Laboratories
11551757 29 Isoxazolyl, oxazolyl, and thiazolylpropionic acid derivatives as potent alpha(4)beta(1) integrin antagonists.EBI Pfizer Inc.
11140722 24 Imide and lactam derivatives of N-benzylpyroglutamyl-L-phenylalanine as VCAM/VLA-4 antagonists.EBI Hoffmann-La Roche Inc.
10853676 13 Discovery and evaluation of potent, cysteine-based alpha4beta1 integrin antagonists.EBI Celltech Chiroscience
10782674 50 N-benzylpyroglutamyl-L-phenylalanine derivatives as VCAM/VLA-4 antagonists.EBI Hoffmann-La Roche Inc.
21316228 28 Discovery of a potent, orally bioavailable pyrimidine VLA-4 antagonist effective in a sheep asthma model.EBI Elan Pharmaceuticals, Inc.
7650686 3 Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist.EBI Merck Research Laboratories
22575869 61 Structure-activity relationship of a series of non peptidic RGD integrin antagonists targetinga5ß1: part 1.EBI AstraZeneca
22572578 124 Structure-activity relationship of a series of non peptidic RGD integrin antagonists targetinga5ß1: part 2.EBI AstraZeneca
20055426 30 Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro-inverso cyclotetrapeptide mimetics.EBI Universita degli Studi di Bologna
18331794 20 Selective cell adhesion inhibitors: Barbituric acid based alpha4beta7--MAdCAM inhibitors.EBI Millennium Pharmaceuticals
18226905 60 Synthesis and SAR of pyridazinone-substituted phenylalanine amide alpha4 integrin antagonists.EBI Johnson& Johnson Pharmaceutical Research& Development
18303826 48 Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues.EBI Universit£ di Parma
15357991 20 Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligands.EBI 3-Dimensional Pharmaceuticals, Inc
12139455 78 Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agents.EBI Genentech Inc.
9191954 9 Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.EBI Merck Research Laboratories
20172716 3 Ultrasmall particle of iron oxide--RGD peptidomimetic conjugate: synthesis and characterisation.EBI Universit£ Catholique de Louvain
17973471 24 Multiple N-methylation by a designed approach enhances receptor selectivity.EBI Technische Universität München
17869121 32 Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one scaffolds.EBI Università di Bologna
17616113 63 Design and synthesis of a new class of selective integrin alpha5beta1 antagonists.EBI Jerini AG
17387018 74 Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective alphavbeta3 inhibitor: design, synthesis, and optimization.EBI Pfizer Global Research and Development
17118652 15 Highly constrained bicyclic VLA-4 antagonists.EBI Merck Research Laboratories
16298127 80 Convergent, parallel synthesis of a series of beta-substituted 1,2,4-oxadiazole butanoic acids as potent and selective alpha(v)beta3 receptor antagonists.EBI Pfizer Inc.
15974570 30 Ligand binding analysis for human alpha5beta1 integrin: strategies for designing new alpha5beta1 integrin antagonists.EBI Università di Napoli Federico II
15715463 16 Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core.EBI Johnson and Johnson Pharmaceutical Research & Development
15109641 4 Rational design and synthesis of novel heparan sulfate mimetic compounds as antiadhesive agents.EBI RIKEN Discovery Research Institute
15081035 24 Bioisosteric replacement of anilide with benzoxazole: potent and orally bioavailable antagonists of VLA-4.EBI Merck Research Laboratories
15006384 179 Synthesis of cinnamic acids and related isosteres as potent and selective alpha v beta 3 receptor antagonists.EBI Pfizer Inc.
14741263 67 Solid-phase synthesis of a small library of 3-phenylthio-3-nicotinyl propionic acid derivatives acting as antagonists of the integrin alphaVbeta3.EBI Nerviano
14741249 21 Aza-bicyclic amino acid sulfonamides as alpha(4)beta(1)/alpha(4)beta(7) integrin antagonists.EBI Johnson & Johnson Pharmaceutical Research & Development
14698164 39 Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds.EBI Pharmaceutical Research Institute
14667228 3 Synthesis and structure-activity relationship of mannose-based peptidomimetics selectively blocking integrin alpha4beta7 binding to mucosal addressin cell adhesion molecule-1.EBI Technische Universität München
12852971 8 Improvement of biological activity and proteolytic stability of peptides by coupling with a cyclic peptide.EBI Kyowa Hakko Kogyo Co., Ltd.
12699755 4 Nonpeptide RGD antagonists: a novel class of mimetics, the 5,8-disubstituted 1-azabicyclo[5.2.0]nonan-2-one lactam.EBI Université Montpellier I
12617914 116 N-(3-phenylsulfonyl-3-piperidinoyl)-phenylalanine derivatives as potent, selective VLA-4 antagonists.EBI Merck Research Laboratories
12565960 33 Thiophene-based vitronectin receptor antagonists.EBI Shire BioChem Inc.
12270174 34 Solid-phase synthesis of dual alpha4beta1/alpha4beta7 integrin antagonists: two scaffolds with overlapping pharmacophores.EBI Genentech
12161161 94 N-Cycloalkanoyl-L-phenylalanine derivatives as VCAM/VLA-4 antagonists.EBI Roche Research Center
12127538 26 N-aryl-prolyl-dipeptides as potent antagonists of VLA-4.EBI Merck Research Laboratories
12039589 6 Focused library approach for identification of new N-acylphenylalanines as VCAM/VLA-4 antagonists.EBI Roche Research Center
12031329 110 Substituted tetrahydrofuroyl-1-phenylalanine derivatives as potent and specific VLA-4 antagonists.EBI Merck Research Laboratories
11909715 73 Squaric acid derivatives as VLA-4 integrin antagonists.EBI Celltech R&D Ltd
11844689 51 Substituted N-(3,5-dichlorobenzenesulfonyl)-L-prolyl-phenylalanine analogues as potent VLA-4 antagonists.EBI Merck Research Laboratories
11844683 31 The discovery of acylated beta-amino acids as potent and orally bioavailable VLA-4 antagonists.EBI Merck Research Laboratories
11755344 47 The discovery of small molecule carbamates as potent dual alpha(4)beta(1)/alpha(4)beta(7) integrin antagonists.EBI Merck Research Laboratories
11755338 24 Specific and dual antagonists of alpha(4)beta(1) and alpha(4)beta(7) integrins.EBI Merck Research Laboratories
11714601 9 Discovery and evaluation of piperidinyl carboxylic acid derivatives as potent alpha(4)beta(1) integrin antagonists.EBI Bayer AG
11677134 42 Design and synthesis of potent and selective inhibitors of integrin VLA-4.EBI Novartis Institute for Biomedical Research
11591507 79 The discovery of sulfonylated dipeptides as potent VLA-4 antagonists.EBI Merck Research Laboratories
11327582 23 2-Acylimino-3H-thiazoline derivatives: a novel template for platelet GPIIb/IIIa receptor antagonists.EBI Taisho Pharmaceutical Co. Ltd.
10853677 34 Discovery and evaluation of potent, tyrosine-based alpha4beta1 integrin antagonists.EBI Celltech Chiroscience
10782673 6 N-acyl phenylalanine analogues as potent small molecule VLA-4 antagonists.EBI Roche Research Center
10406646 15 Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.EBI SmithKline Beecham Pharmaceuticals
10197962 13 Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action.EBI The DuPont Merck Pharmaceutical Company
10072689 39 Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses.EBI Biogen Inc.
9016328 19 Discovery of potent isoxazoline glycoprotein IIb/IIIa receptor antagonists.EBI DuPont Merck Pharmaceutical Company
8057299 66 Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.EBI Merck Research Laboratories
7507165 139 Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists.EBI Telios Pharmaceuticals, Inc.
1469694 22 Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors.EBI Merck Research Laboratories